

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Combined Pro Forma Net Sales to Net Sales**  
(unaudited)

	Three months ended			
	March 31, 2015			
	Standalone Wright Medical Group, Inc.	Standalone Tornier N.V., recast <sup>(1)</sup>	Revenues divested <sup>(2)</sup>	Non-GAAP combined pro forma net sales
<b>U.S.</b>				
Lower extremities	\$ 41,988	\$ 11,443	\$ (3,897)	\$ 49,534
Upper extremities	3,874	39,413	—	43,287
Biologics	11,133	463	—	11,596
Sports med & other	491	1,605	—	2,096
<b>Total extremities &amp; biologics</b>	<b>57,486</b>	<b>52,924</b>	<b>(3,897)</b>	<b>106,513</b>
Large joint	—	46	—	46
<b>Total U.S.</b>	<b>\$ 57,486</b>	<b>\$ 52,970</b>	<b>\$ (3,897)</b>	<b>\$ 106,559</b>
<b>International</b>				
Lower extremities	\$ 11,796	\$ 2,602	\$ —	\$ 14,398
Upper extremities	1,917	18,115	—	20,032
Biologics	4,492	116	—	4,608
Sports med & other	2,243	2,183	—	4,426
<b>Total extremities &amp; biologics</b>	<b>20,448</b>	<b>23,016</b>	<b>—</b>	<b>43,464</b>
Large joint	—	12,106	—	12,106
<b>Total International</b>	<b>\$ 20,448</b>	<b>\$ 35,122</b>	<b>\$ —</b>	<b>\$ 55,570</b>
<b>Global</b>				
Lower extremities	\$ 53,784	\$ 14,045	\$ (3,897)	\$ 63,932
Upper extremities	5,791	57,528	—	63,319
Biologics	15,625	579	—	16,204
Sports med & other	2,734	3,788	—	6,522
<b>Total extremities &amp; biologics</b>	<b>77,934</b>	<b>75,940</b>	<b>(3,897)</b>	<b>149,977</b>
Large joint	—	12,152	—	12,152
<b>Total net sales</b>	<b>\$ 77,934</b>	<b>\$ 88,092</b>	<b>\$ (3,897)</b>	<b>\$ 162,129</b>

(1) Legacy Tornier product line sales have been recast to reflect the reclassification of cement, instruments and freight from the historical Tornier product line "Large Joints and Other" to the product line associated with those revenues that will be utilized for future revenue reporting.

(2) To reduce from Tornier's historical sales the U.S. sales associated with Tornier's Salto Talaris and Salto XT ankle replacement products and silastic toe replacement products.

**Wright Medical Group N.V.**  
**Supplemental Combined Pro Forma Net Sales Information**  
(unaudited)

**First Quarter 2016 sales growth/(decline)**

<b>Product line</b>	<b>U.S. combined pro forma</b>	<b>Int'l combined pro forma constant currency</b>	<b>Int'l combined pro forma</b>	<b>Global combined pro forma constant currency</b>	<b>Global combined pro forma</b>
Lower extremities	12%	12%	8%	12%	11%
Upper extremities	16%	8%	5%	13%	12%
Biologics	48%	(4%)	(9%)	33%	32%
Sports med & other	2%	(5%)	(9%)	(3%)	(5%)
<b>Total extremities &amp; biologics</b>	17%	7%	3%	14%	13%
Large joint	(43%)	(1%)	(3%)	(1%)	(3%)
<b>Total net sales</b>	17%	5%	2%	13%	12%

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Cash Earnings Per Share to Net Loss from Continuing Operations**  
(in thousands, except per share data--unaudited)

	<b>Three months ended</b>
	<b>March 27, 2016</b>
<b>Net loss from continuing operations, as reported</b>	\$ (39,275)
Other reconciling items:	
Inventory step-up amortization <sup>(1)</sup>	11,360
Non-cash interest expense on 2017 & 2020 convertible notes	7,056
Derivatives mark-to-market adjustments	(6,641)
Transaction and transition costs <sup>(2)</sup>	11,100
CVR mark-to-market adjustments	5,324
Tax effect of reconciling items	(1,705)
<b>Non-GAAP net loss from continuing operations, as adjusted</b>	\$ (12,781)
Add back amortization of intangible assets	6,627
<b>Non-GAAP cash earnings</b>	\$ (6,154)
Weighted-average basic shares outstanding	102,704
<b>Non-GAAP cash earnings per share</b>	\$ (0.06)

<sup>(1)</sup> Impacting Gross Profit.

<sup>(2)</sup> Impacting Gross Profit; Selling, General, and Administrative expense; and Research and Development expense for \$0.1 million, \$10.8 million, and \$0.2 million, respectively.

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from Continuing Operations**  
(in thousands, except per share data--unaudited)

	<b>Three months ended</b>
	<b>March 27, 2016</b>
<b>Net loss from continuing operations</b>	<b>\$ (39,275)</b>
Interest expense, net	11,854
Benefit from income taxes	(891)
Depreciation	13,222
Amortization	6,627
<b>Non-GAAP EBITDA</b>	<b>\$ (8,463)</b>
<b>Reconciling items impacting EBITDA:</b>	
Non-cash share-based compensation expense	3,317
Other income, net	(1,068)
Inventory step-up amortization	11,360
Transaction and transition costs	11,100
<b>Non-GAAP adjusted EBITDA</b>	<b>\$ 16,246</b>